Neurocrine Biosciences Shares Surge Following Q3 Revenue Beat and Raised Guidance
Neurocrine Biosciences (NBIX) experienced a significant stock surge of over 15% on Tuesday, marking its largest intraday gain in six years. The rally followed the company's third-quarter results, which exceeded analyst expectations and included an upward revision of future guidance. The company reported quarterly revenue of $1.1 billion, representing approximately 41% year-over-year growth. This strong financial performance reflects robust demand for its rare disease treatments and has bolstered investor confidence in the company's long-term growth trajectory.
Tickers: $NBIX
Topics: earnings beat guidance raise revenue growth stock price surge